BioPharmSignal logoBioPharmSignal

Biotech News

Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Disc Medicine (IRON)Disc MedicineEarnings

Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 2026 Initial data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF)

Related news

IRONDisc Medicine2026-07-30 12:30 EST

Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update

IRONDisc Medicine2026-05-05 12:30 EST

Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update

RIGLRigel Pharmaceuticals2026-03-03 21:01 EST

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

SNDXSyndax Pharmaceuticals2026-02-26 21:01 EST

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

RCKTRocket Pharmaceuticals2026-02-26 21:00 EST

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

GERNGeron2026-02-25 12:00 EST

Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

RIGLRigel Pharmaceuticals2026-02-24 13:05 EST

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update

SNDXSyndax Pharmaceuticals2026-02-19 12:00 EST

Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

KPTIKaryopharm Therapeutics2026-02-12 12:30 EST

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

View all latest news

Disc Medicine

Hematology Drug Development Disc Medicine develops therapies for serious hematologic diseases by targeting pathways involved in heme biosynthesis and iron regulation. Its portfolio addresses both rare red-blood-cell disorders and anemia associated with chronic disease. Bitopertin in EPP Bitopertin is being evaluated in the Phase 3 APOLLO...

Recent company news

IRONDisc Medicine2026-07-30 12:30 EST

Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update

IRONDisc Medicine2026-06-12 12:30 EST

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

IRONDisc Medicine2026-06-09 12:30 EST

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

IRONDisc Medicine2026-06-02 12:00 EST

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

IRONDisc Medicine2026-06-01 12:30 EST

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Stock data

Close
77.44 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States